Cantabio Pharmaceuticals Inc. | WebDisclosure

Switch to English

10651	Sociétés
226542	Mots-clés
155028	Articles
119935	Communiqués

Accueil
Sociétés
Cantabio Pharmaceuticals Inc.

COMMUNIQUÉ DE PRESSE

publié le 06/02/2024 à 16:00, il y a 2 années 4 mois

Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease
Cantabio Pharmaceuticals, Inc. receives major grant from MJFF for the development of DJ-1 replacement therapy aimed at treating Parkinson's disease by increasing DJ-1 levels in patients and preventing disease progression

Precision Medicine Cantabio Pharmaceuticals MJFF Grant DJ-1 Replacement Therapy Parkinson's Disease

Les Echos

Publié le 26/06/2026 à 17:45, il y a 12 heures 47 minutes

Combined General Meeting, June 25, 2026
Publié le 26/06/2026 à 17:45, il y a 12 heures 47 minutes

Assemblée générale mixte du 25 juin 2026
Publié le 26/06/2026 à 17:45, il y a 12 heures 47 minutes

Descriptif du programme de rachat d'actions
Publié le 26/06/2026 à 14:44, il y a 15 heures 47 minutes

Safran information
Publié le 26/06/2026 à 14:44, il y a 15 heures 47 minutes

Information Safran

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 27/06/2026 à 01:40, il y a 4 heures 52 minutes

Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Publié le 27/06/2026 à 00:00, il y a 6 heures 32 minutes

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Publié le 26/06/2026 à 23:00, il y a 7 heures 32 minutes

Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Publié le 26/06/2026 à 22:50, il y a 7 heures 42 minutes

Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Publié le 26/06/2026 à 22:15, il y a 8 heures 17 minutes

Revive Therapeutics Announces Proposed Private Placement

Voir tout ACCESSWIRE

EQS Group

Publié le 27/06/2026 à 00:05, il y a 6 heures 27 minutes

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Publié le 27/06/2026 à 00:04, il y a 6 heures 28 minutes

Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 6 heures 56 minutes

Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 6 heures 56 minutes

EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Publié le 26/06/2026 à 23:27, il y a 7 heures 4 minutes

EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE